Aligning Pharmaceutical Quality Systems and Product Development

For breakthrough product development, Pharmaceutical Quality System (PQS) requirements need to be followed while supplying suitable flexibility to suit accelerated activities for breakthrough product development timelines. Therefore, the accelerated development Pharmaceutical Quality System (PQS) strategy for each product will be unique, as it depends on the timing of the BT designation.

 

 

 

 

 

 

 

 

 

 

 

 

Image Credit: DS InPharmatics

 

A number of activities that might be considered to accelerate development activities are:

  • Flexibility, on the basis of molecule, available product, and platform knowledge will be needed
  • Just the activities with zero impact on patient safety or product supply should be delayed
  • A quality risk assessment needs to be applied to every activity that will be delayed, and the rationale, and controls required to guarantee delayed activities are completed documented
  • A number of activities that are usually completed before license application might need to be delayed and submitted:
    • Post-submission, complete at inspection
    • Post-inspection, before approval
    • Post-market commitments
  • The manufacturing readiness plan can be employed for the development of internal filing and inspection readiness checklists to safeguard all delayed activities are completed or addressed
    • Any Pharmaceutical Quality System (PQS) deferrals need to be documented in a manufacturing readiness plan and monitored to guarantee completion

About DS InPharmatics 

DS InPharmatics (DSI) provides regulatory, technical, and project management consulting services to healthcare product companies that manufacture and/or market pharmaceuticals, biopharmaceuticals, and cellular and gene therapy products.

Since 2007 we have provided our clients with innovative strategies and exceptional quality work products intended to enhance product development, approval, and marketing presence. Whether advocating CMC strategy, directing CMC operations or developing CMC submission content that represent the best interests of emerging biotech, we focus on the critical CMC issues and build programs that enhance development.

In April 2021 we were thrilled to announce that DSI has just become part of ProductLife Group.

French-headquartered ProductLife Group (PLG) is well-known in the Life Sciences market. It has a track record of successfully managing global outsourcing programs and insourcing services for its international client base. The company is on a mission to help transform human health outcomes by optimizing regulatory affairs, safety & vigilance, and quality compliance for life sciences organizations worldwide.

The fit between our two organizations could not be more perfect. We will complement PLG's growing biotech services portfolio. US biotech sponsors recognize DSI as a leader in consulting for go-to-market strategies and RA pre-market consulting. At the same time, PLG has a strong reputation for managing end-to-end outsourcing of regulatory affairs and pharmacovigilance activities worldwide.

Our merger with PLG will harness our combined strengths, offering our clients on both sides of the Atlantic support with their developed drugs approvals and post-approvals compliance, plus advisory services on the best market strategies to deliver a rapid ROI on their development. Together we will offer our clients increased pharmacovigilance capabilities - including a QPPV; pharmacovigilance consulting; and a fully validated safety database - as well as complementary toxicology-related services; RIM/electronic document management services; and support for medical device regulatory requirements.

We see enormous potential in this new chapter for DSI and you, our clients. As a PLG company, we have the opportunity to become part of a global force in life sciences regulatory and compliance solutions and services, and we're incredibly excited to add our momentum to that effort.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jul 11, 2024 at 1:34 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    DSI, a PLG Company. (2024, July 11). Aligning Pharmaceutical Quality Systems and Product Development. News-Medical. Retrieved on December 09, 2024 from https://www.news-medical.net/whitepaper/20200508/Aligning-Pharmaceutical-Quality-Systems-and-Product-Development.aspx.

  • MLA

    DSI, a PLG Company. "Aligning Pharmaceutical Quality Systems and Product Development". News-Medical. 09 December 2024. <https://www.news-medical.net/whitepaper/20200508/Aligning-Pharmaceutical-Quality-Systems-and-Product-Development.aspx>.

  • Chicago

    DSI, a PLG Company. "Aligning Pharmaceutical Quality Systems and Product Development". News-Medical. https://www.news-medical.net/whitepaper/20200508/Aligning-Pharmaceutical-Quality-Systems-and-Product-Development.aspx. (accessed December 09, 2024).

  • Harvard

    DSI, a PLG Company. 2024. Aligning Pharmaceutical Quality Systems and Product Development. News-Medical, viewed 09 December 2024, https://www.news-medical.net/whitepaper/20200508/Aligning-Pharmaceutical-Quality-Systems-and-Product-Development.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.